Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Original Research

Published on 05 Jun 2023

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma

in Cancer Molecular Targets and Therapeutics

Howard Fine
Tony Reid
Scott Caroen
Bryan Oronsky
Nacer Abrouk
Nicholas Butowski

Frontiers in Oncology

doi 10.3389/fonc.2023.1176448

3,094 views
7 citations

Original Research

Published on 02 Jun 2023

Deciphering the molecular mechanism of enhanced tumor activity of the EGFR variant T790M/L858R using melanoma cell lines

in Cancer Molecular Targets and Therapeutics

Hanshuang Shao
Alan Wells

Frontiers in Oncology

doi 10.3389/fonc.2023.1163504

2,109 views
1 citation

Original Research

Published on 29 May 2023

The intervention effect of Aitongxiao prescription on primary liver cancer rats was evaluated based on high-throughput miRNA sequencing and bioinformatics analysis

in Cancer Molecular Targets and Therapeutics

Lijing Xu
Jinlai Cheng
Zhuoxian Li
Xiaoyu Wen
Yuhao Sun
Meng Xia
Jing Leng

Frontiers in Oncology

doi 10.3389/fonc.2023.1050069

3,503 views
1 citation

Review

Published on 23 May 2023

Pancreatic cancer and exosomes: role in progression, diagnosis, monitoring, and treatment

in Cancer Molecular Targets and Therapeutics

Xingliang Fang
Huanrong Lan
Ketao Jin
Jun Qian

Frontiers in Oncology

doi 10.3389/fonc.2023.1149551

6,122 views
16 citations

Original Research

Published on 22 May 2023

Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications

in Cancer Molecular Targets and Therapeutics

Haotian Shi
Wei Wei
Rong Peng
Haimin Chen
Nian Zhou
Lixia Wu
Wenjun Yu
Wenhao Zhao
Jian Hou
Fan Zhou

Frontiers in Oncology

doi 10.3389/fonc.2023.1185991

2,583 views
2 citations

Original Research

Published on 19 May 2023

Non-oncology drug (meticrane) shows anti-cancer ability in synergy with epigenetic inhibitors and appears to be involved passively in targeting cancer cells

in Cancer Molecular Targets and Therapeutics

Yulu Wang
Amit Sharma
Fangfang Ge
Peng Chen
Yu Yang
Hongjia Liu
Hongde Liu
Chunxia Zhao
Lovika Mittal
Shailendra Asthana

Frontiers in Oncology

doi 10.3389/fonc.2023.1157366

3,848 views
5 citations

Original Research

Published on 18 May 2023

Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study

in Cancer Molecular Targets and Therapeutics

Weili Yang
Haoran Qian
Litao Yang
Pengfei Wang
Hailong Qian
Binbin Chu
Zhuo Liu
Jingyu Sun
Dan Wu
Lifeng Sun

Frontiers in Oncology

doi 10.3389/fonc.2023.1180795

1,943 views
2 citations

Mini Review

Published on 18 May 2023

Computational approaches for drug repurposing in oncology: untapped opportunity for high value innovation

in Cancer Molecular Targets and Therapeutics

Shraddha M. Dalwadi
Andrew Hunt
Mark D. Bonnen
Yohannes T. Ghebre

Frontiers in Oncology

doi 10.3389/fonc.2023.1198284

2,754 views
8 citations

Original Research

Published on 18 May 2023

CEP55 as a promising biomarker and therapeutic target on gallbladder cancer

in Cancer Molecular Targets and Therapeutics

Maotuan Huang
Fuxiu Zhong
Mingyuan Chen
Lingju Hong
Weihong Chen
Xiahenazi Abudukeremu
Feifei She
Yanling Chen

Frontiers in Oncology

doi 10.3389/fonc.2023.1156177

2,775 views
8 citations

Original Research

Published on 16 May 2023

Excavation of diagnostic biomarkers and construction of prognostic model for clear cell renal cell carcinoma based on urine proteomics

in Cancer Molecular Targets and Therapeutics

Yiren Yang
Qingyang Pang
Meimian Hua
Zhao Huangfu
Rui Yan
Wenqiang Liu
Wei Zhang
Xiaolei Shi
Yifan Xu
Jiazi Shi

Frontiers in Oncology

doi 10.3389/fonc.2023.1170567

3,927 views
13 citations

Case Report

Published on 16 May 2023

Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature

in Cancer Molecular Targets and Therapeutics

Yishi Zhang
Wan He
Ke Zhan
Luobin Zhang
Hua Cao
Ruilian Xu

Frontiers in Oncology

doi 10.3389/fonc.2023.1153233

1,959 views
1 citation

Case Report

Published on 12 May 2023

EGFR p.V774M/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report

in Cancer Molecular Targets and Therapeutics

Hai Pan
Linlin Zhang
Fanlu Meng
Shasha Guan
Diansheng Zhong

Frontiers in Oncology

doi 10.3389/fonc.2023.1159308

2,160 views
3 citations

Original Research

Published on 12 May 2023

Xerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers

in Cancer Molecular Targets and Therapeutics

Mark Uhlik
Daniel Pointing
Seema Iyer
Luka Ausec
Miha Štajdohar
Robert Cvitkovič
Matjaž Žganec
Kerry Culm
Valerie Chamberlain Santos
Bronislaw Pytowski

Frontiers in Oncology

doi 10.3389/fonc.2023.1158345

5,025 views
5 citations

Review

Published on 10 May 2023

Gas6/AXL pathway: immunological landscape and therapeutic potential

in Cancer Molecular Targets and Therapeutics

Xiaoqian Zhai
Dan Pu
Rulan Wang
Jiabi Zhang
Yiyun Lin
Yuqing Wang
Ni Zhai
Xuan Peng
Qinghua Zhou
Lu Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1121130

11,371 views
12 citations

Original Research

Published on 09 May 2023

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer

in Cancer Molecular Targets and Therapeutics

Shicheng Yang
Allen Green
Needa Brown
Alexis Robinson
Merline Senat
Bryanna Testino
Daniela M. Dinulescu
Srinivas Sridhar

Frontiers in Oncology

doi 10.3389/fonc.2023.1175617

3,946 views
6 citations

Original Research

Published on 09 May 2023

Establishment, characterization, and drug screening of low-passage patient individual non-small cell lung cancer in vitro models including the rare pleomorphic subentity

in Cancer Molecular Targets and Therapeutics

Ingo Andus
Friedrich Prall
Michael Linnebacher
Christina S. Linnebacher

Frontiers in Oncology

doi 10.3389/fonc.2023.1089681

3,588 views
3 citations